Cardalis 40 mg Tablet (Chewable) is a Health Canada–registered veterinary drug (DIN 02542080) held by Ceva Animal Health Inc, containing Spironolactone. Health Canada lists its status as Marketed (status date 16 Dec 2024). Nexara Health has matched 777 registrations of Spironolactone across 39 other regulated markets, 4 of them in the same strength and dosage form.

Health Canada registration

Spironolactone registered in other markets

777 registrations of the same molecule in 39 national registries outside Canada (first 120 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.

See every manufacturer of Spironolactone worldwide →

Regulator price references for Spironolactone

Published list or reimbursement prices for Spironolactone presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.

Marketed Canadian products with the same active ingredient

Sourcing through Nexara Health

Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.

Frequently asked questions

Is Cardalis (DIN 02542080) marketed in Canada?

Yes. Health Canada lists DIN 02542080 as Marketed as of 16 Dec 2024.

Who holds the Canadian licence for this product?

Ceva Animal Health Inc is the company of record in the Health Canada Drug Product Database.

Is Spironolactone registered outside Canada?

Yes — Nexara Health has matched 777 registrations in 39 other markets, including 4 in the same strength and dosage form (see the table above).

Where does this data come from?

Health Canada Drug Product Database (DPD), DIN 02542080, status date 2024-12-16; national medicine registries: ARCSA registro sanitario, BDA, CMED, CNOPS liste des medicaments, CNS liste positive, DH Drug Office, eEKO (Erstattungskodex), EMA centrally authorised, Fimea Perusrekisteri, HPRA, Laegemiddelstyrelsen, LINAME (formulary), Lyfjastofnun lyfjaverdskra, MISPAS, MoH deltio timwn, NEAK PUPHA, NHRA, PAMI, PBS, SUKL DLP, URPL RPL; price sources: CMED, EDE, eEKO (Erstattungskodex), Lyfjastofnun lyfjaverdskra, MoH deltio timwn, NEAK PUPHA, NHRA, PBS. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.

Source: Health Canada Drug Product Database (DPD), DIN 02542080, status date 2024-12-16; national medicine registries: ARCSA registro sanitario, BDA, CMED, CNOPS liste des medicaments, CNS liste positive, DH Drug Office, eEKO (Erstattungskodex), EMA centrally authorised, Fimea Perusrekisteri, HPRA, Laegemiddelstyrelsen, LINAME (formulary), Lyfjastofnun lyfjaverdskra, MISPAS, MoH deltio timwn, NEAK PUPHA, NHRA, PAMI, PBS, SUKL DLP, URPL RPL; price sources: CMED, EDE, eEKO (Erstattungskodex), Lyfjastofnun lyfjaverdskra, MoH deltio timwn, NEAK PUPHA, NHRA, PBS.

Health Canada Drug Product Database (DPD), DIN 02542080, status date 2024-12-16; national medicine registries: ARCSA registro sanitario, BDA, CMED, CNOPS liste des medicaments, CNS liste positive, DH Drug Office, eEKO (Erstattungskodex), EMA centrally authorised, Fimea Perusrekisteri, HPRA, Laegemiddelstyrelsen, LINAME (formulary), Lyfjastofnun lyfjaverdskra, MISPAS, MoH deltio timwn, NEAK PUPHA, NHRA, PAMI, PBS, SUKL DLP, URPL RPL; price sources: CMED, EDE, eEKO (Erstattungskodex), Lyfjastofnun lyfjaverdskra, MoH deltio timwn, NEAK PUPHA, NHRA, PBS. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.